Back to Research

Organization profile

Amporin Pharmaceuticals

Amporin Pharmaceuticals is a Swiss clinical-stage biotechnology startup that develops first-in-class small molecule drugs to target the amyloid pores responsible for neurodegenerative cell death. The company’s vision is to provide acute oral disease-modifying treatments for major conditions such as Parkinson's disease and ALS by repairing cellular membranes and restoring homeostasis.

Basel, SwitzerlandFounded 2024

Overview

1. Executive Summary (Confidence: High)

Amporin Pharmaceuticals is a high-potential entrant in the longevity and neurodegeneration sectors, founded in April 2024 in Basel, Switzerland.[33] The organization is pioneering a breakthrough scientific approach that shifts the therapeutic focus away from insoluble amyloid fibrils—which have largely failed in clinical trials—toward toxic soluble misfolded protein oligomers.[33] These oligomers aggregate into "amyloid pores" that puncture holes in cell membranes, causing a lethal influx of calcium and subsequent degeneration.[34] Amporin's leadership team, consisting of Big Pharma veterans from Roche, Novartis, and various biotechs, is developing a pipeline of small molecule inhibitors categorized as Amporbans, Amporins, and Amportacs.[33] Having already secured seed validation through the Venture Kick program, the organization is currently building a robust in vitro data package to support its first clinical targets in Parkinson's and ALS.[33]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.